Sign up
Pharma Capital

CytoDyn adds new talent to its management team

CytoDyn Inc (OTCMKST:CYDY) CEO Dr Nader Pourhassan and Dr Richard Pestell tell Proactive Investors the biotech has added two senior executives to its management team as it seeks regulatory approval of its flagship drug leronlimab (PRO 140) to treat cancer and HIV.

Dr Pestell added more insights and color into CytoDyn's recent announcement about beginning pre-clinical studies with leronlimab to treat Non-Alcoholic Steatohepatitis (NASH).

 

View full CYDY profile View Profile
View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.